Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
George Church

George Church

George Church is an American genetic scientist, Harvard University professor, and entrepreneur.


George Church is Professor of Genetics at Harvard Medical School, head of Synthetic Biology at Harvard's Weiss Institute, and Director of, which provides open-access information on human Genomic, Environmental & Trait data (GET). He received his PhD from Harvard in 1984.

He has contributed to many DNA sequencing methods and companies, including CGI-BGI, Life, Illumina, and Nanopore. He is director of an IARPA BRAIN Project and NIH Center for Excellence in Genomic Science. His honors include election to NAS & NAE & Franklin Bower Laureate for Achievement in Science. He has coauthored 453 papers, 105 patent publications, and one book, Regenesis..

In addition to his writing, Church was involved in the genesis of the Human Genome Project in 1984, Personal Genome Project in 2005 and has helped found over 30 startups. Church's PhD developed methods for direct genome sequencing, multiplexing and barcoding which directly led to the first genome sequence in 1994.


Church has been involved in a large number of companies and institutions in his career, acting in a range of roles such as scientist, professor, founder and advisor. In addition to the companies he has co-founded, he currently works in an advisor role at multiple biochemistry and genealogy companies including Flagship Ventures, 23andMe, Good Start Genetics, Genia and Genome Compiler Corp.


January 2009
Church becomes a founding member of the Wyss Institute for Biologically Inspired Engineering.
December 13, 2005
Church initiates the Personal Genome Project, an open-access human genome of trait data sets.
Church publishes the first direct genomic sequencing method as part of his Ph.D in Biochemistry at Harvard University.
August 28, 1954
George Church was born.


Further Resources


Famed geneticist George Church predicts the future of mankind


Emma Betuel
September 13, 2021
There are a growing number of companies interested in CRISPR's potential to upend medicine. It's probably safe to say there's only one company interested in using the gene-editing system to create a living, breathing woolly mammoth. Or, at least, something pretty close to it. That's the primary mission of a new company called Colossal. Co-founded [...]
Antonio Regalado
August 24, 2021
MIT Technology Review
Jason Kelly has promised a manufacturing revolution with DNA. Just don't ask him to make any products.
April 21, 2021
Seed Health, a microbial sciences company developing next-generation probiotic applications and live biotherapeutics, announced the close of a $40 million Series A financing led by impact investor, The Craftory, alongside TechBio investor ARTIS Ventures and life science investor GISEV, with participation from existing investors, Founders Fund and 8VC.
Andrea Park
April 20, 2021
Nowadays, you can buy pretty much any piece of digital memorabilia as a non-fungible token: a $69 million work of art, an X-ray of William Shatner's teeth and, soon, George Church's entire genome.
Amirah Al Idrus
April 19, 2021
Rejuvenate Bio raised more than $10 million in its series A round to propel its gene therapy toward the market for the treatment of heart disease in dogs and toward the clinic for the treatment of aging-related conditions in humans, including heart failure, kidney failure, Type 2 diabetes and obesity.


Golden logo
By using this site, you agree to our Terms & Conditions.